Comparison of serum humoral responses induced by oral immunization with the hepatitis B virus core antigen and the cholera toxin B subunit

Clinical and Vaccine Immunology

Volumn 15, Issue 5, 2008, Pages 852-858

  Broos, Katleen ^a   Janssens, Michiel E ^a   De Goeyse, Ine ^a   Vanlandschoot, Peter ^c,d   Leroux Roels, Geert ^c   Geysen, Dirk ^b   Guisez, Yves ^a  

^a UNIVERSITY OF ANTWERP   (Belgium)

^b INSTITUTE OF TROPICAL MEDICINE   (Belgium)

^c GHENT UNIVERSITY HOSPITAL   (Belgium)

^d ABLYNX NV   (Belgium)

Author keywords

[No Author keywords available]

Indexed keywords

CHOLERA TOXIN B SUBUNIT; HEPARAN SULFATE; HEPATITIS B CORE ANTIGEN; IMMUNOGLOBULIN A; IMMUNOGLOBULIN G1; IMMUNOGLOBULIN G2A; BACTERIUM ANTIBODY; CHOLERA TOXIN; HEPATITIS B ANTIBODY; HYBRID PROTEIN; VIRUS ANTIGEN;

ANTIBODY DETECTION; ARTICLE; CONTROLLED STUDY; HUMORAL IMMUNITY; IMMUNE RESPONSE; IMMUNIZATION; IMMUNOGENICITY; IMMUNOGLOBULIN BLOOD LEVEL; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; TH1 CELL; TH2 CELL; WESTERN BLOTTING; ANIMAL; BAGG ALBINO MOUSE; BLOOD; CLASSIFICATION; GENETICS; HEPATITIS B VIRUS; IMMUNOLOGY; METABOLISM; ORAL DRUG ADMINISTRATION;

ADMINISTRATION, ORAL; ANIMALS; ANTIBODIES, BACTERIAL; ANTIGENS, VIRAL; CHOLERA TOXIN; HEPATITIS B ANTIBODIES; HEPATITIS B CORE ANTIGENS; HEPATITIS B VIRUS; IMMUNIZATION; MICE; MICE, INBRED BALB C; RECOMBINANT FUSION PROTEINS;

EID: 46249098936     PISSN: 15566811     EISSN: 1556679X     Source Type: Journal    
DOI: 10.1128/CVI.00382-07     Document Type: Article

References (72)

1. Areas, A. P., M. L. Oliveira, C. R. Ramos, M. E. Sbrogio-Almeida, I. Raw, and P. L. Ho. 2002. Synthesis of cholera toxin B subunit gene: cloning and expression of a functional 6Xhistagged protein in Escherichia coli. Protein Expr. Purif. 25:481-487.
2. Ball, J. M., M. E. Hardy, R. L. Atmar, M. E. Conner, and M. K. Estes. 1998. Oral immunization with recombinant Norwalk virus-like particles induces a systemic and mucosal immune response in mice. J. Virol. 72:1345-1353.
3. Birnbaum, F., and M. Nassal. 1990. Hepatitis B virus nucleocapsid assembly: primary structure requirements in the core protein. J. Virol. 64:3319-3330.
4. Blanchard, T. G., N. Lycke, S. J. Czinn, and J. G. Nedrud. 1998. Recombinant cholera toxin B subunit is not an effective mucosal adjuvant for oral immunization of mice against Helicobacter felis. Immunology 94:22-27.
5. Bradford, M. M. 1976. A rapid and sensitive method for the quantitation of microgram quantities of protein utilizing the principle of protein-dye binding. Anal. Biochem. 72:248-254.
6. Broos, K., P. Vanlandschoot, M. Maras, J. Robbens, G. Leroux-Roels, and Y. Guisez. 2007. Expression, purification and characterization of full-length RNA-free hepatitis B core particles. Protein Expr. Purif. 54:30-37.
7. Bruna-Romero, O., C. D. Rocha, M. Tsuji, and R. T. Gazzinelli. 2004. Enhanced protective immunity against malaria by vaccination with a recombinant adenovirus encoding the circumsporozoite protein of Plasmodium lacking the GPI-anchoring motif. Vaccine 22:3575-3584.
8. Cooper, A., G. Tal, O. Lider, and Y. Shaul. 2005. Cytokine induction by hepatitis B virus capsid in macrophages is facilitated by membrane heparin sulfate and involves TLR2. J. Immunol. 175:3165-3176.
9. Cooper, A., and Y. Shaul. 2006. Clathrin-mediated endocytosis and lysosomal cleavage of hepatitis B virus capsid-like core particles. J. Biol. Chem. 281:16563-16569.
10. Coutelier, J. P., J. T. van der Logt, F. W. Heessen, G. Warnier, and J. Van Snick. 1987. IgG2a restriction of murine antibodies elicited by viral infections. J. Exp. Med. 165:64-69.
11. Cox, E., F. Verdonck, D. Vanrompay, and B. Goddeeris. 2006. Adjuvants modulating mucosal immune responses or directing systemic responses towards the mucosa. Vet. Res. 37:511-539.
12. de Aizpurua, H. J., and G. J. Russell-Jones. 1988. Oral vaccination. Identification of classes of proteins that provoke an immune response upon oral feeding. J. Exp. Med. 167:440-451.
13. De Filette, M., W. Min Jou, A. Birkett, K. Lyons, B. Schultz, A. Tonkyro, S. Resch, and W. Fiers. 2005. Universal influenza A vaccine: optimization of M2-based constructs. Virology 337:149-161.
14. Fiers, W., M. De Filette, A. Birkett, S. Neirynck, and W. Min Jou. 2004. A "universal" human influenza A vaccine. Virus Res. 103:173-176.
15. Fifis, T., A. Gamvrellis, B. Crimeen-Irwin, G. A. Pietersz, J. Li, P. L. Mottram, I. F. McKenzie, and M. Plebanski. 2004. Size-dependent immunogenicity: therapeutic and protective properties of nano-vaccines against tumors. J. Immunol. 173:3148-3154.
16. Fingerut, E., B. Gutter, R. Meir, D. Eliahoo, and J. Pitcovski. 2005. Vaccine and adjuvant activity of recombinant subunit B of E. coli enterotoxin produced in yeast. Vaccine 23:4685-4696.
17. Gamvrellis, A., D. Leong, J. C. Hanley, S. D. Xiang, P. Mottram, and M. Plebanski. 2004. Vaccines that facilitate antigen entry into dendritic cells. Immunol. Cell Biol. 82:506-516.
18. Garside, P., and A. M. Mowat. 2001. Oral tolerance. Semin. Immunol. 13:177-185.
19. Giannasca, P. J., K. T. Giannasca, P. Falk, J. I. Gordon, and M. R. Neutra. 1994. Regional differences in glycoconjugates of intestinal M cells in mice: potential targets for mucosal vaccines. Am. J. Physiol. 267:G1108-G1121.
20. Giddings, G., G. Allison, D. Brooks, and A. Carter. 2000. Transgenic plants as factories for biopharmaceuticals. Nat. Biotechnol. 18:1151-1155.
21. Giroglou, T., L. Florin, F. Schafer, R. E. Streeck, and M. Sapp. 2001. Human papillomavirus infection requires cell surface heparan sulfate. J. Virol. 75:1565-1570.
22. Giudice, E. L., and J. D. Campbell. 2006. Needle-free vaccine delivery. Adv. Drug Deliv. Rev. 58:68-89.
23. Guisez, Y., I. Fache, L. A. Campfield, F. J. Smith, A. Farid, G. Plaetinck, J. Van der Heyden, J. Tavernier, W. Fiers, P. Burn, and R. Devos. 1998. Efficient secretion of biologically active recombinant OB protein (leptin) in Escherichia coli, purification from the periplasm and characterization. Protein Expr. Purif. 12:249-258.
24. Holmgren, J., J. Adamsson, F. Anjuère, J. Clemens, C. Czerkinsky, K. Eriksson, C. F. Flach, A. George-Chandy, A. M. Harandi, M. Lebens, T. Lehner, M. Lindblad, E. Nygren, S. Raghavan, J. Sanchez, M. Stanford, J. B Sun, A. M. Svennerholm, and S. Tengvall. 2005. Mucosal adjuvants and anti-infection and anti-immunopathology vaccines based on cholera toxin, cholera toxin B subunit and CpG DNA. Immunol. Lett. 97:181-188.
25. Huang, Z., G. Elkin, B. J. Maloney, N. Beuhner, C. J. Arntzen, Y. Thanavala, and H. S. Mason. 2005. Virus-like particle expression and assembly in plants: hepatitis B and Norwalk viruses. Vaccine 23:1851-1858.
26. Huyghebaert, N., A. Vermeire, P. Rottiers, E. Remaut, and J. P. Remon. 2005. Development of an enteric-coated, layered multi-particulate formulation for ileal delivery of viable recombinant Lactococcus lactis. Eur. J. Pharm. Biopharm. 61:134-141.
27. Ismail, N., and P. A. Bretscher. 1999. The Th1/Th2 nature of concurrent immune responses to unrelated antigens can be independent. J. Immunol. 163:4842-4850.
28. Koschel, M., R. Thomssen, and V. Bruss. 1999. Extensive mutagenesis of the hepatitis B virus core gene and mapping of mutations that allow capsid formation. J. Virol. 73:2153-2160.
29. Kovarik, J., M. Gaillard, X. Martinez, P. Bozzotti, P. H. Lambert, T. F. Wild, and C. A. Siegrist. 2001. Induction of adult-like antibody, Th1, and CTL responses to measles hemagglutinin by early life murine immunization with an attenuated vaccinia-derived NYVAC(K1L) viral vector. Virology 285:12-20.
30. Kratz, P. A., B. Böttcher, and M. Nassal. 1999. Native display of complete foreign protein domains on the surface of hepatitis B virus capsids. Proc. Natl. Acad. Sci. USA 96:1915-1920.
31. Lachmann, S., H. Meisel, C. Muselmann, D. Koletzki, H. R. Gelderblom, G. Borisova, D. H. Kruger, P. Pumpens, and R. Ulrich. 1999. Characterization of potential insertion sites in the core antigen of hepatitis B virus by the use of a short-sized model epitope. Intervirology 42:51-56.
32. Laemmli, U. K. 1970. Cleavage of structural proteins during the assembly of the head of bacteriophage T4. Nature 227:680-685.
33. Lal, P., V. G. Ramachandran, R. Goyal, and R. Sharma. 2007. Edible vaccines: current status and future. Indian J. Med. Microbiol. 25:93-102.
34. Lamphear, B. J., S. J. Streatfield, J. M. Jilka, C. A. Brooks, D. K. Barker, D. D. Turner, D. E. Delaney, M. Garcia, B. Wiggins, S. L. Woodard, E. E. Hood, I. R. Tizard, B. Lawhorn, and J. A. Howard. 2002. Delivery of subunit vaccines in maize seed. J. Control. Release 85:169-180.
35. Lesieur, C., M. J. Cliff, R. Carter, R. F. James, A. R. Clarke, and T. R. Hirst. 2002. A kinetic model of intermediate formation during assembly of cholera toxin B-subunit pentamers. J. Biol. Chem. 277:16697-16704.
36. Li, T., N. Takeda, and T. Miyamura. 2001. Oral administration of hepatitis E virus-like particles induces a systemic and mucosal immune response in mice. Vaccine 19:3476-3484.
37. Lobaina, Y., D. Garcia, N. Abreu, V. Muzio, and J. C. Aguilar. 2003. Mucosal immunogenicity of the hepatitis B core antigen. Biochem. Biophys. Res. Commun. 300:745-750.
38. Ludwig, D. S., R. K. Holmes, and G. K. Schoolnik. 1985. Chemical and immunochemical studies on the receptor binding domain of cholera toxin B subunit. J. Biol. Chem. 260:12528-12534.
39. Marinaro, M., H. F. Staats, T. Hiroi, R. J. Jackson, M. Coste, P. N. Boyaka, N. Okahashi, M. Yamamoto, H. Kiyono, H. Bluethmann, K. Fujihashi, and J. R. McGhee. 1995. Mucosal adjuvant effect of cholera toxin in mice results from induction of T helper 2 (Th2) cells and IL-4. J. Immunol. 155:4621-4629.
40. Markine-Goriaynoff, D., and J. P. Coutelier. 2002. Increased efficacy of the immunoglobulin G2a subclass in antibody-mediated protection against lactate dehydrogenase-elevating virus-induced polioencephalomyelitis revealed with switch mutants. J. Virol. 76:432-435.
41. + T-cell responses following delivery of human immunodeficiency virus type 1 Tat protein by recombinant adenylate cyclase of Bordetella pertussis. J. Virol. 79:9872-9884.
42. Mazumdar, T., K. Anam, and N. Ali. 2004. A mixed Th1/Th2 response elicited by a liposomal formulation of Leishmania vaccine instructs Th1 responses and resistance to Leishmania donovani in susceptible BALB/c mice. Vaccine 22:1162-1171.
43. Milich, D. R., J. Hughes, J. Jones, M. Sällberg, and T. R. Phillips. 2001. Conversion of poorly immunogenic malaria repeat sequences into a highly immunogenic vaccine candidate. Vaccine 20:771-788.
44. Milich, D. R., M. Chen, F. Schödel, D. L. Peterson, J. E. Jones, and J. L. Hughes. 1997. Role of B cells in antigen presentation of the hepatitis B core. Proc. Natl. Acad. Sci. USA 94:14648-14653.
45. Milich, D. R., D. L. Peterson, J. Zheng, J. L. Hughes, R. Wirtz, and F. Schodel. 1995. The hepatitis nucleocapsid as a vaccine carrier moiety. Ann. N. Y. Acad. Sci. 754:187-201.
46. Milich, D. R., and A. McLachlan. 1986. The nucleocapsid of hepatitis B virus is both a T-cell-independent and a T-cell-dependent antigen. Science 234:1398-1401.
47. Missiakas, D., J. M. Betton, and S. Raina. 1996. New components of protein folding in extracytoplasmic compartments of Escherichia coli SurA, FkpA and Skp/OmpH. Mol. Microbiol. 21:871-884.
48. Neirynck, S., T. Deroo, X. Saelens, P. Vanlandschoot, W. Min Jou, and W. Fiers. 1999. A universal influenza A vaccine based on the extracellular domain of the M2 protein. Nat. Med. 5:1157-1163.
49. Newman, M., F. M. Suk, M. Cajimat, P. K. Chua, and C. Shik. 2003. Stability and morphology comparisons of self-assembled virus-like particles from wild-type and mutant human hepatitis B virus capsid proteins. J. Virol. 77:12950-12960.
50. Perez Filgueira, D. M., A. Berinstein, E. Smitsaart, M. V. Borca, and A. M. Sadir. 1995. Isotype profiles induced in Balb/c mice during foot and mouth disease (FMD) virus infection or immunization with different FMD vaccine formulations. Vaccine 13:953-960.
51. Petersen, J. S., S. Bregenholt, V. Apostolopolous, D. Homann, T. Wolfe, A. Hughes, K. De Jongh, M. Wang, T. Dyrberg, and M. G. Von Herrath. 2003. Coupling of oral human or porcine insulin to the B subunit of cholera toxin (CTB) overcomes critical antigenic differences for prevention of type I diabetes. Clin. Exp. Immunol. 134:38-45.
52. Plotnicky-Gilquin, H., D. Cyblat-Chanal, J. P. Aubry, T. Champion, A. Beck, T. Nguyen, J. Y. Bonnefoy, and N. Corvaia. 2002. Gamma interferon-dependent protection of the mouse upper respiratory tract following parenteral immunization with a respiratory syncytial virus G protein fragment. J. Virol. 76:10203-10210.
53. Pumpens, P., and E. Grens. 2001. HBV core particles as a carrier for B cell/T cell epitopes. Intervirology 44:98-114.
54. Pumpens, P., G. P. Borisova, R. A. Crowther, and E. Grens. 1995. Hepatitis B virus core particles as epitope carriers. Intervirology 38:63-74.
55. Rose, R. C., C. Lane, S. Wilson, J. A. Suzich, E. Rybicki, and A. L. Williamson. 1999. Oral vaccination of mice with human papillomavirus virus-like particles induces systemic virus-neutralizing antibodies. Vaccine 17:2129-2135.
56. Schodel, F., D. Peterson, D. R. Milich, Y. Charoenvit, J. Sadoff, and R. Wirtz. 1997. Immunization with hybrid hepatitis B virus core particles carrying circumsporozoite antigen epitopes protects mice against Plasmodium yoelii challenge. Behring Inst. Mitt. 98:114-119.
57. Schodel, F., R. Wirtz, D. Peterson, J. Hughes, R. Warren, J. Sadoff, and D. Milich. 1994. Immunity to malaria elicited by hybrid hepatitis B virus core particles carrying circumsporozoite protein epitopes. J. Exp. Med. 180:1037-1046.
58. Schonberger, O., T. R. Hirst, and O. Pines. 1991. Targeting and assembly of an oligomeric bacterial enterotoxoid in the endoplasmic reticulum of Saccharomyces cerevisiae. Mol. Microbiol. 5:2663-2671.
59. Streatfield, S. J., and J. A. Howard. 2003. Plant production systems for vaccines. Expert Rev. Vaccines 2:763-775.
60. Surcel, H. M., M. Troye-Blomberg, S. Paulie, G. Andersson, C. Moreno, G. Pasvol, and J. Ivanyi. 1994. Th1/Th2 profiles in tuberculosis, based upon proliferation and the cytokine response of blood lymphocytes to mycobacterial antigens. Immunology 81:171-176.
61. Tacket, C. O., M. B. Sztein, G. A. Losonsky, S. S. Wasserman, and M. K. Estes. 2003. Humoral, mucosal, and cellular immune responses to oral Norwalk virus-like particles in volunteers. Clin. Immunol. 108:241-247.
62. Tacket, C. O., and H. S. Mason. 1999. A review of oral vaccination with transgenic vegetables. Microbes Infect. 1:777-783.
63. Reference deleted.
64. Ulrich, R., A. Lundkvist, H. Meisel, D. Koletzki, K. B. Sjolander, H. R. Gelderblom, G. Borisova, P. Schnitzler, G. Darai, and D. H. Kruger. 1998. Chimaeric HBV core particles carrying a defined segment of Puumala hantavirus nucleocapsid protein evoke protective immunity in an animal model. Vaccine 16:272-280.
65. Vanlandschoot, P., F. Van Houtte, B. Serruys, and G. Leroux-Roels. 2007. Contamination of a recombinant hepatitis B virus nucleocapsid preparation with a human B-cell activator. J. Virol. 81:2535-2536.
66. Vanlandschoot, P., F. Van Houtte, B. Serruys, and G. Leroux-Roels. 2005. The arginine-rich carboxy-terminal domain of the hepatitis B virus core protein mediates attachment of the nucleocapsids to cell-surface-expressed heparan sulphate. J. Gen. Virol. 86:75-84.
67. Velikovsky, C. A., F. A. Goldbaum, J. Cassataro, S. Estein, R. A. Bowden, L. Bruno, C. A. Fossati, and G. H. Giambartolomei. 2003. Brucella lumazine synthase elicits a mixed Th1-Th2 immune response and reduces infection in mice challenged with Brucella abortus 544 independently of the adjuvant formulation used. Infect. Immun. 71:5750-5755.
68. Wardrop, R. M., and C. C. Whitacre. 1999. Oral tolerance in the treatment of inflammatory autoimmune diseases. Inflamm. Res. 48:106-119.
69. Webster, D. E., S. D. Smith, R. J. Pickering, R. A. Strugnell, I. B. Dry, and S. L. Wesselingh. 2006. Measles virus hemagglutinin protein expressed in transgenic lettuce induces neutralising antibodies in mice following mucosal vaccination. Vaccine 24:3538-3544.
70. Yao, Q. 2003. Enhancement of mucosal immune responses by chimeric influenza HA/SHIV virus-like particles. Res. Initiat. Treat. Action 8:20-21.
71. Yu, J., H. Webb, and T. R. Hirst. 1992. A homologue of the Escherichia coli DsbA protein involved in disulphide bond formation is required for enterotoxin biogenesis in Vibrio cholerae. Mol. Microbiol. 6:1949-1958.
72. Zhang, X., N. A. Buehner, A. M. Hutson, M. K. Estes, and H. S. Mason. 2006. Tomato is a highly effective vehicle for expression and oral immunization with Norwalk virus capsid protein. Plant Biotechnol. J. 4:419-432.